AstraZeneca PLC (LON:AZN)
12,824
-156 (-1.20%)
Oct 23, 2026, 4:39 PM BST
AstraZeneca Employees
AstraZeneca had 96,100 employees as of December 31, 2025. The number of employees increased by 1,800 or 1.91% compared to the previous year. That makes AstraZeneca the 314th largest employer in the world and 9th in the United Kingdom.
Employees
96,100
Change (1Y)
1,800
Growth (1Y)
1.91%
Revenue / Employee
481.29K GBP
Profits / Employee
81.93K GBP
Market Cap
198.90B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 96,100 | 1,800 | 1.91% |
| Dec 31, 2024 | 94,300 | 4,400 | 4.89% |
| Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
| Dec 31, 2022 | 83,500 | 400 | 0.48% |
| Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| GSK plc | 66,841 |
| Haleon | 24,535 |
| Spire Healthcare Group | 17,800 |
| Smith & Nephew | 17,000 |
| Convatec Group | 10,000 |
| Hikma Pharmaceuticals | 9,500 |
| CVS Group | 9,000 |
| Genus | 2,921 |
AstraZeneca News
- 14 hours ago - Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer - Business Wire
- 2 days ago - China-made cancer drug to go on sale in US after Americans travel to buy it - South China Morning Post
- 2 days ago - AstraZeneca PLC Announces US FDA Accelerated Approval of Ultomiris for IgAN on 22 October 2026 - Nasdaq
- 2 days ago - AstraZeneca announces US availability of Zegfrovy - TheFly
- 2 days ago - ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations - Business Wire
- 2 days ago - ZEGFROVY (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations - Wallstreet:Online
- 2 days ago - AstraZeneca's Ultomiris Gets FDA Accelerated Approval As First C5 Inhibitor For IgAN - Nasdaq
- 3 days ago - AstraZeneca's Ultomiris Receives Accelerated FDA Approval for Kidney Disease Treatment - GuruFocus